TRANSDISCIPLINARITY IN STRATEGIC DECISIONS FOR ONCOLOGICAL TREATMENTS

Area of Science:

• Oncology
• Health Economics
• Bioethics

Background:

• Current models for equity and access to novel oncological treatments are strained by economic and demographic crises in Europe.
• Rising costs of innovative cancer drugs exacerbate these challenges, impacting patient access and care quality.

Purpose of the Study:

• To highlight the need for a patient-centered care model in oncology.
• To emphasize the importance of interdisciplinary and transdisciplinary approaches in cancer treatment and drug approval.
• To address ethical considerations including informed consent, therapeutic privilege, utilitarianism, social justice, and economic principles in public health services.

Main Methods:

• This study is a conceptual analysis and synthesis of current challenges in oncological care.
• It reviews ethical principles and economic factors influencing access to innovative cancer treatments.
• It advocates for a collaborative, transdisciplinary decision-making framework.

Main Results:

• A patient-centered care plan, grounded in evidence-based practice, is essential for patient well-being.
• Physician focus on the doctor-patient relationship and informed consent are critical, particularly with new medications.
• Balancing ethical considerations (human dignity, social justice) with economic realities is necessary for public health services.

Conclusions:

• An interdisciplinary approach is vital for the approval of new oncological drugs.
• Transdisciplinary decision-making involving civil society, pharmaceutical companies, healthcare professionals, and policymakers is essential.
• This collaborative approach is key to ensuring quality, innovation, and equity in oncological care.